Coca-Cola Consolidated leverages its exclusive Coca-Cola partnership and elite brand to drive strong pricing power and consistent revenue growth, even amid volume declines. The company boasts a superior balance sheet, low leverage, and robust capital returns through buybacks and dividends. My DCF analysis shows COKE is 17% undervalued, with conservative assumptions supporting a significant margin of safety for investors.

Tesla has been forced to offer discounts of up to 40% to U.K. car leasing companies, The Times reported on Monday, citing industry sources. It comes as Elon Musk's company scrambles to reverse a declining sales trend across Europe.

Kinetik Holdings offers a 7.6% yield and trades near $41, presenting attractive value despite recent commodity price headwinds and project delays. EBITDA guidance was trimmed by 5% due to lower commodity prices and delayed growth projects, but long-term growth projects like Kings Landing and ECCC remain on track. The company is 84% fee-based, limiting commodity exposure, and targets 10% annual EBITDA growth over five years, with potential for a sale at a premium valuation.

Buffett's Berkshire reshapes its portfolio with big bets on UnitedHealth and housing, while trimming Apple and Bank of America. The big bets put focus on ETFs like IHF and ITB.

White House trade adviser Peter Navarro wrote a strongly worded column in the Financial Times calling the dramatic increase in India's purchases of Russian oil since the invasion of Ukraine “opportunistic and deeply corrosive” of a global effort to isolate the Kremlin and curb Vladimir Putin's war machine. Lillianna Byington of Bloomberg Government has more.

ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. - Favorable safety profile – No severe adverse events; limited, typically mild to moderate, transient, and …

I initiate my coverage on Eli Lilly with a 'Buy' after an eventful Q2 earnings season. The stock looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and Mounjaro sales. LLY management is confident that the momentum in the weight loss segment will hold up. FY 2025 guidance was revised upwards for both the top and bottom lines.

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SoHo House (NYSE: SHCO) for possible breaches of fiduciary duty and other violations of law in its going-private transaction. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of SoHo House will receive $9.00 per share in cash implying a total enterprise value of approximately $2.7 billi.

Deal adds premium brands and North Carolina footprint; pipeline remains active at 4-6× EBITDA valuation range with 20-45% non-cash consideration NEW YORK, NY / ACCESS Newswire / August 18, 2025 / Capstone Holding Corp. (NASDAQ:CAPS), a national building products distribution platform, today announced it has signed a definitive agreement to acquire Carolina Stone Products, with closing targeted by August 22, 2025, subject to customary conditions. Additional details are included in the Company's Form 8-K filed today.

Dividends are one of the oldest and most reliable forms of returning capital to shareholders, dating back centuries. Income investing focuses on cash flows, providing a reliable foundation even when market prices fluctuate. Every time we collect a dividend payment, we win!

ETFs that combine investing and politics tap into investors' polarized views. Why they shouldn't get your vote.

The market is now halfway through the year's earnings, which is arguably one of the most important seasons of all because it will close in on the possible ranges for the next two quarters and the year-end financials. That being said, many retail and professional investors are beginning to price in their opinions for the companies they find of interest, causing prices to swing all over the place.

Kfar Saba, Israel, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced that it has received a purchase order for its advanced Counter-Unmanned Aerial Systems (C-UAS) solution from a defense entity. This is another achievement for ParaZero in its continued expansion into the defense market and the rapidly growing counter-drone market specifically. According to recent market research, the global anti drone market size was valued at $2.4B in 2024. The market is projected to …

Tesla, Rivian, and Lucid all profit from selling regulatory credits to rivals who haven't sold enough EVs. Now, the Trump administration is gutting the credit scheme, and it's causing the three companies a serious headache.

Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for "treatment of Behçet's Disease" following review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients with …

TORONTO , Aug. 18, 2025 /PRNewswire/ - DeFi Technologies Inc. (the "Company" or " DeFi Technologies") (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance, today announced the launch of the DeFi Technologies Insights Symposium, with the inaugural session to take place in Frankfurt, Germany , on September 25, 2025 . The DeFi Technologies Insights Symposium is a new global initiative designed to foster high-level, in-person discussions around the future of finance.

BitMine Crypto Holdings Exceed $6.612 billion, including 1.52 million ETH Tokens BitMine Crypto holdings of $6.6 billion ETH is a $1.7 billion increase from $4.9 billion reported last week BitMine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, and Galaxy Digital to support BitMine's goal of acquiring 5% of ETH LAS VEGAS , Aug. 18, 2025 /PRNewswire/ -- (NYSE AMERICAN: BMNR) BitMine Immersion Technologies ("BitMine" or the "Company") today announced crypto holdings exceeding $6.612 billion. As of August 17th at 11:59pm ET, the Company's crypto holdings …

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan's largest office landlord, today announced that its board of directors has declared a monthly ordinary dividend of $0.2575 per share of common stock, which is the equivalent of an annualized dividend of $3.09 per share. The dividend is payable in cash on September 15, 2025 to shareholders of record at the close of business on August 29, 2025.

MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced a long-term strategic partnership with Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in advanced cardiovascular imaging solutions. The collaboration reflects Circle CVI's commitment to leveraging trusted, high-quality data to drive innovation in cardiac diagnostics, treatment planning, and AI model development with data being delivered in the next 30 days.

I hunt investments that combine safety, income, and growth, avoiding hype and focusing on long-term, high-quality opportunities. Some areas are unloved and undervalued, offering income, potential growth, and protection against inflation, perfect for patient investors. I seek places with professional management, liquidity, and dual potential, giving me both steady income and the chance for capital gains.